Roivant Sciences Ltd

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Roivant Sciences reports strong Q1 earnings and explores new opportunities

Roivant Sciences demonstrated strong financial performance, with positive results for key programs and a substantial cash position. While facing challenges in patent litigation and DTC campaign optimization, the company has opportunities to leverage payer work, explore new therapeutic potentials, and capitalize on transaction opportunities.

ROIV reports positive trial results and potential in autoimmune diseases

ROIV's earnings call highlights positive trial results, potential in autoimmune diseases, and upcoming Phase III study results. The company acknowledges challenges in proving efficacy in lupus but is optimistic about brepocitinib's potential in various indications.

Roivant Sciences doubles revenue in Q3, VTAMA gains traction

Roivant Sciences delivered strong financial results and progress in its pipeline, particularly with the successful launch of VTAMA and enrollment in key studies.
While facing challenges in market penetration and patient behavior trends, the company's strategic focus on innovation and financial discipline positions it for future success.
By leveraging opportunities in expanding indications, advancing pipeline assets, and strategic collaborations, Roivant is poised for sustained growth and value creation.

Roivant Sciences reports robust Q4 earnings and strategic growth outlook

Roivant Sciences delivered a strong financial performance with notable achievements in clinical programs and a robust cash position, indicating stability and growth potential.
While facing challenges in patient consent for biomarker analysis and legal uncertainties, the company is strategically positioned to leverage opportunities in expanding its pipeline and exploring new markets.
With a focus on balancing operational challenges and pursuing strategic growth initiatives, Roivant Sciences remains well-positioned for future success in the biopharmaceutical industry.

Roivant Sciences excels in Q1 2024 with promising autoimmune therapies

Roivant Sciences demonstrated strong performance and promising results in Q1 2024 across multiple programs
Brepocitinib's unique mechanism positions it as a potential leader in autoimmune therapies, with significant market opportunities
Capital decisions post-Immunovant data and pricing strategy alignment present challenges for Roivant
Opportunities lie in rapid commercial launches, blockbuster potential in orphan indications, and prescription acceleration strategies

Roivant Sciences excels in Q2 with $7B cash post-sale

Roivant Sciences delivered a solid performance in Q2 2024, showcasing financial strength, positive clinical outcomes, and strategic focus on value creation. While facing challenges in margin optimization and market competition, the company is well-positioned to leverage opportunities in unmet medical needs and strategic partnerships for growth.

Roivant Sciences reports strong Q3 performance and outlines growth plans

Roivant Sciences showcased strong performance with key successes and efficient development models. The company faces challenges in certain clinical trials but remains optimistic about growth opportunities. By focusing on strategic growth and efficient execution, Roivant aims to capitalize on its promising pipeline and commercial potential.

Roivant Sciences excels in Q4, eyes blockbuster sales and strategic partnerships

Roivant Sciences is strategically positioned with a focus on maximizing pipeline opportunities, prioritizing data-driven decisions, and capitalizing on the differentiation potential of brepocitinib.

Roivant Sciences excels in Q2 with strong pipeline and financials

Roivant Sciences showcased strong financial performance, a robust late-stage pipeline, and positive clinical trial data in Q2 2025.
The company faces challenges in managing expectations, pricing strategies, and balancing capital return with R&D investments.
Opportunities for growth include upcoming data releases, strategic partnerships, and optimizing business strategies for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

Biotech firm Roivant Sciences on Thursday launched a company with Pfizer Inc focused on an experimental bowel disease treatment, as the drugmakers seek to tap into a multibillion dollar market.

Roivant, Pfizer team up on inflammatory disease drug

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) and Pfizer Inc. (NYSE: PFE) today announced formation of a new Vant to develop and commercialize PF-06480605 (now RVT-3101). RVT-3101 is a fully human monoclonal antibody targeting TL1A, which is currently in Phase 2b development in ulcerative colitis (UC). The Vant has the exclusive option to collaborate with Pfizer on a next-generation TL1A directed antibody which recently entered Phase 1.

Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q2 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Jeffrey Kalmus - Head, Strategic Finance Matt Gline - CEO Conference Call Participants David Risinger - SVB Securities Brian Cheng - J.P.

Roivant Sciences Ltd. (ROIV) Q2 2022 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of -2.44% and 86.73%, respectively, for the quarter ended September 2022.

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2022 and provided an update on the Company's operations.

Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update

NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer, will present a poster at the 37th Annual Meeting of The Society for Immunotherapy of Cancer (SITC) highlighting preclinical data for AFVT-2101 (previously AFM32).

Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the pricing of its primary and secondary public offering of 30,000,000 common shares of Roivant, consisting of 20,000,000 common shares offered by Roivant and 10,000,000 common shares offered by the selling shareholders at a price to the public of $5.00 per share for total gross proceeds of $150 million, consisting of total gross proceeds to Roivant of approximately $100 million and total gross proceeds to the selling shareholders of approximately $50 million. In addition, Roivant has granted the underwriter a 30-day option to purchase up to $22.5 million additional common shares. Roivant expects its cash position will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of calendar year 2025. Roivant will not receive any of the proceeds from the sale of its common shares by the selling shareholders. The offering is expected to close on November 10, 2022, subject to customary closing conditions.

Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering

Roivant Sciences Ltd. (ROIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Analysts Estimate Roivant Sciences Ltd. (ROIV) to Report a Decline in Earnings: What to Look Out for

Roivant Sciences Ltd. (ROIV) was a big mover last session on higher-than-average trading volume.

Roivant Sciences Ltd. (ROIV) Soars 5.8: Is Further Upside Left in the Stock?

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. EST on Monday, November 14, 2022 to report its financial results for the second quarter ended September 30, 2022 and provide a corporate update.

Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences

iMedia Brands

Snow Lake Resources Ltd

PEDEVCO

Best penny stocks to buy? Check out these 4 stocks to watch under $4.

Best Penny Stocks To Buy Now? 4 Under $4 To Watch Today

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) will participate in three healthcare investor conferences and hold an investor day in September:

Roivant to Participate in September Investor Events

The stock price of Roivant Sciences Ltd (ROIV) fell by 2.75% in the previous trading session. This is why.

Roivant Sciences Ltd (ROIV) Stock: Why It Fell 2.75%

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q1 2022 Earnings Conference Call August 15, 2022 8:00 AM ET Company Participants Paul Davis - Head of Communications Matt Gline - CEO Conference Call Participants David Risinger - SVB Securities Dennis Ding - Jefferies Neena Bitritto-Garg - Citi Louise Chen - Cantor Fitzgerald Douglas Tsao - HC Wainwright Corinne Jenkins - Goldman Sachs Brendan Smith - Cowen Alexander Xenakis - Truist Securities Operator Good day, and thank you for standing by.

Roivant Sciences Ltd. (ROIV) CEO Matt Gline on Q1 2022 Results - Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of -60% and 33.04%, respectively, for the quarter ended June 2022.

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today reported its financial results for the first quarter ended June 30, 2022 and provided an update on the Company's operations.

Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. EDT on Monday, August 15, 2022 to report its financial results for the first quarter ended June 30, 2022 and provide a corporate update.

Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q4 2021 Results Earnings Conference Call June 28, 2022 8:00 AM ET Company Participants Paul Davis - Head, Communications Matt Gline - Chief Executive Officer Richard Pulik - Chief Financial Officer Frank Torti - Vant Chair Eric Venker - President and Chief Operating Officer Mayukh Sukhatme - President and Chief Investment Officer Conference Call Participants Dennis Ding - Jefferies Yaron Werber - Cowen Louise Chen - Fitzgerald Neena Bitritto-Garg - Citi David Risinger - SVB Securities Corinne Jenkins - Goldman Sachs Operator Good day, and thank you for standing by.

Roivant Sciences Ltd. (ROIV) CEO Matt Gline on Q4 2021 Results - Earnings Call Transcript

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today reported its financial results for the fourth quarter and fiscal year ended March 31, 2022 and provided an update on the Company's operations.

Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update

NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences and Pfizer today announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality. Priovant was established in September 2021 through a transaction between Roivant (Nasdaq: ROIV) and Pfizer (NYSE: PFE), in which Pfizer licensed oral and topical brepocitinib's global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25% equity ownership interest in Priovant.

Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 15, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. EDT on Tuesday, June 28, 2022 to report its financial results for the fourth quarter and fiscal year ended March 31, 2022 and provide a corporate update.

Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022

- EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and secondary endpoints and demonstrated highly statistically significant improvement versus vehicle in Physician Global Assessment (PGA) score with 36% of patients versus 6% in vehicle in PSOARING 1 and 40% of patients versus 6% in vehicle in PSOARING 2 achieving clear or almost clear with a minimum 2-grade improvement at week 12 (p

FDA Approves Dermavant's VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) will participate in four upcoming healthcare investor conferences:

Roivant to Present at Upcoming Investor Conferences

NEW YORK and INGELHEIM, Germany, April 20, 2022 (GLOBE NEWSWIRE) -- VantAI, an AI-first induced-proximity company, and Boehringer Ingelheim today announced that the two companies have entered into an early discovery research collaboration focused on degrading traditionally “undruggable” targets. The collaboration will initially focus on one degrader program combined with multiple proprietary E3 ligase platforms. The two organizations and their scientists will leverage VantAI's geometric deep learning platform to computationally streamline the design of new molecules optimized for each E3 platform, leveraging unique target-E3 interface contacts to create innovative routes for important drug parameters such as potency and selectivity.

VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders

NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- VantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (‘Janssen'). The agreement was facilitated by Johnson & Johnson Innovation.

News for Roivant Sciences Ltd Stock (ROIV)